Compare FOFO & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOFO | CCEL |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | Hong Kong | United States |
| Employees | 14 | N/A |
| Industry | | Managed Health Care |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 29.6M |
| IPO Year | N/A | 2022 |
| Metric | FOFO | CCEL |
|---|---|---|
| Price | $3.63 | $3.53 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 51.9K | 9.6K |
| Earning Date | 03-13-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 3.84% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $11.09 | $390.96 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $2.86 | $2.72 |
| 52 Week High | $68.00 | $5.76 |
| Indicator | FOFO | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 49.99 |
| Support Level | $3.78 | $3.18 |
| Resistance Level | $5.74 | $3.57 |
| Average True Range (ATR) | 0.47 | 0.30 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 17.32 | 22.73 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.